In Brief: Sandoz
This article was originally published in The Tan Sheet
Sandoz: Receives Aug. 9 NDA approval for reformulation of Tavist-D tablets to bilayer, film-coated capsules. Product strength and ingredients will remain unchanged. Sandoz awaits FDA approval of a common cold indication for Tavist-D and Tavist-1; the Nonprescription and Pulmonary-Allergy Drugs Advisory Committees concluded last year that company data support the new indication ("The Tan Sheet" Nov. 20, 1995, p. 5)...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC